Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...
Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...
Please provide your email address to receive an email when new articles are posted on . Intravenous golimumab for JIA maintained an acceptable risk-benefit profile in a long-term extension study. The ...
The approvals cover Gobivaz 50 mg/0.5 mL and 100 mg/mL in pre-filled syringes and autoinjectors, for treating adults with rheumatoid arthritis (with methotrexate), psoriatic arthritis (with or without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback